fluoxetine has been researched along with arginine vasopressin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Altemus, M; Cizza, G; Gold, PW | 1 |
| Gibbs, DM | 1 |
| Gibbs, DM; Vale, W | 1 |
| Baylis, PH; Butler, TJ; Charlton, JA; Faull, CM | 1 |
| Baylis, PH; Butler, T; Charlton, JA; Faull, CM; Phillips, E; Thornton, S | 1 |
| De Bellis, MD; Geracioti, TD; Gold, PW; Kling, MA; Listwak, SJ | 1 |
| Delville, Y; Ferris, CF; Fuller, RW; Koppel, G; Melloni, RH; Perry, KW | 1 |
| Donald, RA; Inder, WJ; Joyce, PR; Mulder, RT; Prickett, TC | 1 |
| Ferris, CF; Koppel, G; Messenger, T; Rasmussen, MF | 1 |
| Lolait, SJ; O'Carroll, AM; Roper, JA; Stewart, LQ; Young, WS | 1 |
| Araya, AV; Fiedler, JL; Guajardo, V; Herrera, L; Heskia, C; Lara, P; López, P; Marín, F; Rojas, G; Sasso, J; Symon, A; Ventura-Juncá, R | 1 |
| Carlini, VP; de Cuneo, MF; Perez, MF; Poretti, MB; Rask-Andersen, M; Sawant, RS; Schiöth, HB | 1 |
| Albers, HE; Hardcastle, N; Larkin, TE; Norvelle, A; Riaz, A; Song, Z; Terranova, JI | 1 |
1 review(s) available for fluoxetine and arginine vasopressin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluoxetine and arginine vasopressin
| Article | Year |
|---|---|
Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Analysis of Variance; Arginine Vasopressin; Depression; Female; Fluoxetine; Humans; Hydrocortisone; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric | 2001 |
13 other study(ies) available for fluoxetine and arginine vasopressin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro.
Topics: Animals; Arginine Vasopressin; Desipramine; Fluoxetine; Hypothalamus; Male; Rats; Rats, Sprague-Dawley; Reference Values; Trazodone | 1992 |
Measurement of hypothalamic corticotropin-releasing factors in hypophyseal portal blood.
Topics: Adrenocorticotropic Hormone; Animals; Arginine Vasopressin; Corticotropin-Releasing Hormone; Fluoxetine; Hypothalamus; Male; Oxytocin; Pituitary Gland; Rats; Serotonin | 1985 |
Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood.
Topics: Adrenocorticotropic Hormone; Animals; Arginine Vasopressin; Corticotropin-Releasing Hormone; Fluoxetine; Kinetics; Male; Pituitary Gland, Anterior; Propylamines; Rats; Serotonin | 1983 |
The effect of acute pharmacological manipulation of central serotonin neurotransmission on osmoregulated secretion of arginine vasopressin in the rat.
Topics: Amphetamines; Animals; Arginine Vasopressin; Fluoxetine; Male; Rats; Rats, Wistar; Ritanserin; Secretory Rate; Serotonin; Serotonin Antagonists; Water-Electrolyte Balance | 1993 |
The effect of modulation of central serotonin neurotransmission on osmoregulated vasopressin release in rats.
Topics: Animals; Arginine Vasopressin; Brain; Fluoxetine; Hematocrit; Male; Rats; Rats, Wistar; Serotonin; Sodium Chloride; Synaptic Transmission; Water-Electrolyte Balance | 1993 |
Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.
Topics: Adult; Arginine Vasopressin; Corticotropin-Releasing Hormone; Depression, Chemical; Depressive Disorder; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales | 1993 |
Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters.
Topics: Aggression; Animals; Arginine Vasopressin; Behavior, Animal; Cricetinae; Fluoxetine; Hypothalamus, Anterior; Male; Mesocricetus; Microinjections; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Vasopressin; Selective Serotonin Reuptake Inhibitors; Serotonin; Vasoconstrictor Agents | 1997 |
Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Aggression; Animals; Arginine Vasopressin; Behavior, Animal; Clomipramine; Cricetinae; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Grooming; Hair; Hypothalamus; Male; Microinjections; Obsessive-Compulsive Disorder; Pigmentation; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2001 |
The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine Vasopressin; Corticosterone; Corticotropin-Releasing Hormone; Desipramine; Female; Fluoxetine; Hypothalamo-Hypophyseal System; Male; Mice; Mice, Knockout; Oxytocin; Paraventricular Hypothalamic Nucleus; Pituitary-Adrenal System; Receptors, Vasopressin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Sex Factors | 2008 |
Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Arginine Vasopressin; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Polymorphism, Genetic; Prospective Studies; Psychiatric Status Rating Scales; Receptors, Corticotropin-Releasing Hormone; Receptors, Glucocorticoid; Tacrolimus Binding Proteins; Treatment Outcome; Young Adult | 2014 |
Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Corticotropin-Releasing Hormone; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hypothalamus; Male; Mice; Olfactory Bulb; Receptors, Corticotropin-Releasing Hormone; Receptors, Vasopressin; Signal Transduction; Venlafaxine Hydrochloride | 2016 |
Serotonin and arginine-vasopressin mediate sex differences in the regulation of dominance and aggression by the social brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Animals; Arginine Vasopressin; Behavior, Animal; Female; Fluoxetine; Hypothalamus; Male; Mesocricetus; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Sex Characteristics; Social Dominance | 2016 |